PharmaJet® and Invectys partner for cancer vaccine.
French biopharmaceutical developer Invectys recently received FDA approval for its DNA based cancer vaccine INVAC-1 to proceed to Phase II clinical trial. The go-ahead also includes innovation in drug delivery using PharmaJet’s needle-free Tropis® injection system, to deliver clinical doses of the therapeutic vaccine to trial participants.
The delivery system, which received CE Mark authorization two years ago, proved its success clinically in Phase I trials. "We believe the PharmaJet Needle-free device offers many advantages to patients and providers including less pain and stress, elimination of needles and provides a more precise and consistent method for vaccine delivery," said Invectys CEO, Pierre Langlade Demoyen.
With more than 25 million people living with cancer, 14 million being diagnosed and another 8 million dying each year (WHO) all recognize cancer’s burden on the world’s populations. A vaccine that can be infused topically has great potential to improve dose safety and compliance while boosting therapeutic value and effectiveness.
PharmaJet CEO, Ron Lowy, offered his optimistic view noting: "We are pleased that the PharmaJet Tropis Intradermal device has been chosen as the method of administration for this important cancer immunotherapy vaccine development.” The Needle-free device, said Lowy, “has already been used successfully in numerous clinical studies for nucleic acid (DNA or RNA) vaccine delivery."
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.